We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Trellus Health Plc | TRLS | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.05 | 9.09% | 0.60 | 16:22:55 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.55 | 0.55 | 0.675 | 0.60 | 0.55 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 12/12/2024 15:55 by tia01 It’s been a horrible week in trls with sells and few if any buys keeping the shares at all time lows.Any news leak could cause a huge positive reaction rally which would be welcome news for current shareholders nursing huge losses |
Posted at 07/12/2024 14:51 by ravenrussia I am also looking into buying this next week as bio technology companies are now being tipped as the best sector to be in.From what i have read today TRLS are waiting on some important deals from America They seem to have enough cash to last well into final quarter of 2025 ( assuming no revenues at all) I will be buying some on Monday |
Posted at 05/12/2024 16:03 by allesandro Guys this just popped up on my radar,any LTH give a quick outline of what is happening at TRLS ? why the big fall in share price ? all i see is positive RNS |
Posted at 31/10/2024 11:02 by tomboyb Probably the easiest Job in the world -Sit back / relax /spend and when money runs out point out market conditions - Those TRLS videos are there to see - No shame - |
Posted at 29/4/2024 15:16 by blackhorse23 AlliancePharma [APH] has an impressive record of long-term growth & creating sustainable value for our shareholders & stakeholders-DIVIDEN |
Posted at 24/4/2024 17:09 by davr0s Crikey I inherited some of these as a dividend payment from EKF some years ago. My holding is currently valued at £1.90 lol. What am I supposed to do with this?? |
Posted at 01/12/2023 12:24 by hatfullofsky TRLS are now trading 40% below their cash level |
Posted at 01/9/2023 12:06 by hatfullofsky Breakeven is on the IMC slide deckAt $100 per patient per month, breakeven at 6200 members (2.5% of TAM)Cash at $19m 2022 v $24m 2021, burn below $700k per month in 2023, cash into 2025 (at current revenue levels and capital investment)In early and late stage discussions with several health plans 2023 expecting revenue take off as 2022 pilot contracts roll into commercial agreements.130 patients currently enrolled (a long way to 6200)TRLS need to announce contracts and enrolment numbers for this to recover |
Posted at 11/4/2023 08:31 by mikemine1 TRLS seems to fit right in there with the Commission's view of the future. Well done Wan. |
Posted at 13/2/2023 07:55 by wan With today's news, that now completes 3 of contracts highlighted in Trellus' Half-year Report -Significant progress with advancing B2B2C model I am very pleased to report that, despite the longer lead times in the B2B2C contracting process as previously reported in December 2021, we have made significant progress in advancing a number of conversations with payers , such as regional and national health plans, employers, health systems, GI provider networks, and pharmaceutical companies. Whilst we have launched our D2C model, we remain focused on our B2B2C offering which provides better quality patient outcomes at lower costs to health plans and employers. We are in productive conversations with two health plans, having entered late-stage discussions with one and starting the due diligence process with another; we are in the final contracting phase for a New York Medicaid plan and we have two further contracts, one with a large NY State employer and the other with a NY State Provider to support members of a large NY labor union, which we expect to be signed soon. We are in late-stage discussions with two large pharmaceutical companies in the US, one for patient support services and another for clinical trials screening, and we are in ongoing discussions with two patient services partners who deliver programs to pharmaceutical companies as part of a centralized patient support hub. We believe that our methodology will help pharmaceutical companies to improve patient adherence behaviors, encourage customer loyalty and engagement, and support clinical trial screening. Success under our B2B2C model will see those organisations driving their own members to the Trellus platform. Expansion into Irritable Bowel Syndrome (IBS) for comprehensive GI solution Hopefully we will see continued execution in IBS expansion and the pharma discussions/contract |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
